

# **2023-2027 Italy Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers**

<https://marketpublishers.com/r/24C5BF95E32EEN.html>

Date: September 2023

Pages: 0

Price: US\$ 2,800.00 (Single User License)

ID: 24C5BF95E32EEN

## **Abstracts**

LeadingMarketResearch.com's new report is a study of the major business opportunities emerging in the Italian cancer diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report examines trends in the Italian cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

### **Rationale**

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

## Italy Market Overview

Five-year test volume and sales projections.

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Estimated universe of laboratories performing cancer diagnostic testing.

Cancer statistics, etiology and recent developments.

## Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

## Over 200 Current and Emerging Cancer Diagnostic Test

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

## Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test.

Five-year test volume and sales forecasts for major tumor markers by market segment, including:

Hospitals

Commercial/Private Laboratories

## Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

## Technology Assessment

Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,

chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies

and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Perkin Elmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others. Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

## Contents

### **I. INTRODUCTION**

### **II. WORLDWIDE MARKET OVERVIEW**

### **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

### **IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

### **V. ALTERNATIVE MARKET PENETRATION STRATEGIES**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

### **VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

### **VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW**

- A. Cancer Statistics and Etiology
  - 1. Breast Cancer

2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
- B. Major Current and Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembryonic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Tumor Markers
  27. Oncogenes

&nbsp;&nbsp; Abl/abl-bcr

&nbsp;&nbsp; AIB1

&nbsp;&nbsp; BCL-2

&nbsp;&nbsp; BRCA1

&nbsp;&nbsp; CD44

&nbsp;&nbsp; C-fos

&nbsp;&nbsp; C-myb

&nbsp;&nbsp; C-myc

&nbsp;&nbsp; CYP-17

&nbsp;&nbsp; Erb-B

&nbsp;&nbsp; HPC1

&nbsp;&nbsp; N-myc

&nbsp;&nbsp; P40

&nbsp;&nbsp; P51

&nbsp;&nbsp; P53

&nbsp;&nbsp; PIK3CA

&nbsp;&nbsp; PTI-1

&nbsp;&nbsp; Ras

&nbsp;&nbsp; Reg

&nbsp;&nbsp; Sis

&nbsp;&nbsp; Src and others

## 28. Polypeptide Growth Factors

&nbsp;&nbsp; Basic Fibroblast Growth Factor

&nbsp;&nbsp; Beta-TGF

&nbsp;&nbsp; Cachectin (TNT)

&nbsp;&nbsp; Calmodulin

&nbsp;&nbsp; ECFR

&nbsp;&nbsp; Nerve Growth Factor (NGF)

&nbsp;&nbsp; Epidermal Growth Factor (EGF)

&nbsp;&nbsp; Ornithine Decarboxylase

&nbsp;&nbsp; Transferrin

&nbsp;&nbsp; Transforming Growth Factor-Alpha

## 29. Ectopic Hormones

## 30. Colony Stimulating Factors

## 31. Lymphokines

&nbsp;&nbsp; Alpha-Interferon

&nbsp;&nbsp; B Cell Growth Factors

&nbsp;&nbsp; B Cell Growth Factor (BCGF)

&nbsp;&nbsp; Gamma-Interferon



&nbsp;&nbsp; Interleukin-1 (IL-1)  
&nbsp;&nbsp; Macrophage Activating Factor  
32. Immunohistochemical Stains  
33. Emerging Tumor Markers  
&nbsp;&nbsp; N-Acetylglucosamine  
&nbsp;&nbsp; Actin  
&nbsp;&nbsp; Alpha-Actin  
&nbsp;&nbsp; Antineuronal Antibodies  
&nbsp;&nbsp; 7B2  
&nbsp;&nbsp; B72.3  
&nbsp;&nbsp; Bax  
 &nbsp; BCD-F9  
&nbsp;&nbsp; BLCA-4  
&nbsp;&nbsp; Blood Group Antigens A,B,H  
&nbsp;&nbsp; CA  
&nbsp;&nbsp; CA 72-4/TAG-72  
&nbsp;&nbsp; CA  
&nbsp;&nbsp; CA-242  
&nbsp;&nbsp; CA-549  
&nbsp;&nbsp; CAM  
&nbsp;&nbsp; CAR-3  
&nbsp;&nbsp; Cathepsin-D  
&nbsp;&nbsp; Chromogranin A and B  
&nbsp;&nbsp; Cluster 1 Antigen  
&nbsp;&nbsp; Cluster-5/5A Antigen  
&nbsp;&nbsp; CTA  
&nbsp;&nbsp; CU18  
&nbsp;&nbsp; DR-70  
&nbsp;&nbsp; DU-PAN-2  
&nbsp;&nbsp; Endometrial Bleeding Associated Factor  
&nbsp;&nbsp; Endostatin  
&nbsp;&nbsp; Epithelial Membrane Antigen  
&nbsp;&nbsp; Feulgen Hydrolysis  
&nbsp;&nbsp; Fibronectin  
&nbsp;&nbsp; FSH  
&nbsp;&nbsp; (1-\$\$\$3)-L-fucosyltransferase  
&nbsp;&nbsp; Gastrin-Releasing Peptide (GRP)  
&nbsp;&nbsp; GDCFP-15  
&nbsp;&nbsp; Glucagon

&nbsp;&nbsp; Glycoamines  
&nbsp;&nbsp; H23  
&nbsp;&nbsp; Her-2  
&nbsp;&nbsp; Human Carcinoma Antigen  
&nbsp;&nbsp; HPA  
&nbsp;&nbsp; HSP27  
&nbsp;&nbsp; Intermediate Filaments  
&nbsp;&nbsp; Cytokeratins/CK18/Cyfra 21-1  
&nbsp;&nbsp; Desmin  
&nbsp;&nbsp; Gliofibrillary Acid Protein  
&nbsp;&nbsp; Neurofilaments  
&nbsp;&nbsp; Vimentin  
&nbsp;&nbsp; KA  
&nbsp;&nbsp; Kinases  
&nbsp;&nbsp; KP16D3  
&nbsp;&nbsp; LAI  
&nbsp;&nbsp; Leukocyte Common Antigen  
&nbsp;&nbsp; Lewis Antigens  
&nbsp;&nbsp; Lysophosphatidic Acid (LPA)  
&nbsp;&nbsp; Ma 695/Ma  
&nbsp;&nbsp; MABDF3  
&nbsp;&nbsp; MAG  
&nbsp;&nbsp; ME1  
&nbsp;&nbsp; Minactivin  
&nbsp;&nbsp; MN/CA9  
&nbsp;&nbsp; MSA  
&nbsp;&nbsp; Mucin Cancer Antigen (MCA)  
&nbsp;&nbsp; Multiple Tumor Suppressor  
&nbsp;&nbsp; Myosin  
&nbsp;&nbsp; NEA-130  
&nbsp;&nbsp; NMP22  
&nbsp;&nbsp; OA-519  
&nbsp;&nbsp; Opioid Peptides  
&nbsp;&nbsp; P-glycoprotein  
&nbsp;&nbsp; Pancreatic Oncofetal Antigen (POA)  
&nbsp;&nbsp; Placental Lactogen  
&nbsp;&nbsp; PR92  
&nbsp;&nbsp; Proliferative Index, Ki-67  
&nbsp;&nbsp; Px

&nbsp;&nbsp; RB Inactivation/Deletion

&nbsp;&nbsp; Ret

&nbsp;&nbsp; SCCL

&nbsp;&nbsp; Selectin

&nbsp;&nbsp; Sialic Acid

&nbsp;&nbsp; Sialyl SSEA-1/SLX

&nbsp;&nbsp; SN10

&nbsp;&nbsp; Somatostatin

&nbsp;&nbsp; TA-90

&nbsp;&nbsp; TABA

&nbsp;&nbsp; Tachykinin

&nbsp;&nbsp; TAG

&nbsp;&nbsp; TPS

&nbsp;&nbsp; Troponin

&nbsp;&nbsp; Tubulin

&nbsp;&nbsp; VCAM

&nbsp;&nbsp; VEGF

&nbsp;&nbsp; Villen and others

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

3. Molecular Diagnostics

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

E. Personal Testing

## **VIII. COUNTRY ANALYSIS**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Dynamics, Trends, Size and Growth
  - &nbsp;&nbsp; Volume Forecasts by Test and Market Segment
  - &nbsp;&nbsp; Sales Forecasts by Test and Market Segment
  - &nbsp;&nbsp; Major Supplier Sales and Market Shares

## **IX. COMPETITIVE PROFILES**

The report provides strategic assessments of over 30 leading cancer diagnostics market players

and start-up companies with innovative technologies and products, including:

- &nbsp;&nbsp; Abbott
- &nbsp;&nbsp; Affymetrix
- &nbsp;&nbsp; Beckman Coulter/Danaher/Cepheid
- &nbsp;&nbsp; Becton Dickinson
- &nbsp;&nbsp; bioMerieux
- &nbsp;&nbsp; Bio-Rad
- &nbsp;&nbsp; DiaSorin
- &nbsp;&nbsp; Eiken Chemical
- &nbsp;&nbsp; Elitech Group
- &nbsp;&nbsp; Enzo Biochem
- &nbsp;&nbsp; Fujifilm Wako
- &nbsp;&nbsp; Fujirebio
- &nbsp;&nbsp; Grifols
- &nbsp;&nbsp; Hologic
- &nbsp;&nbsp; Leica Biosystems
- &nbsp;&nbsp; PerkinElmer
- &nbsp;&nbsp; Qiagen
- &nbsp;&nbsp; QuidelOrtho
- &nbsp;&nbsp; Roche
- &nbsp;&nbsp; Siemens Healthineers
- &nbsp;&nbsp; Takara Bio
- &nbsp;&nbsp; Thermo Fisher and others.

## I would like to order

Product name: 2023-2027 Italy Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/24C5BF95E32EEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/24C5BF95E32EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970